Compared side by side
HGH vs tesamorelin: how they differ
The short answer
HGH is recombinant growth hormone itself; tesamorelin is a synthetic GHRH analogue that stimulates the body’s own GH secretion. Both are FDA-approved for narrow uses: HGH for GH deficiency and several growth disorders, tesamorelin to reduce excess abdominal fat in HIV lipodystrophy, where in two phase 3 trials it cut visceral fat about 15% in 26 weeks. Both are daily shots.
Side by side
| Compared | HGH | Tesamorelin |
|---|---|---|
| Category | Growth hormone | Growth hormone |
| Also known as | GH, rHGH, Human Growth Hormone, Growth Hormone, Somatropin, hGH | Egrifta |
| What it is | Recombinant human growth hormone — an identical copy of the GH your pituitary makes. | The only GHRH analog currently FDA-approved (to reduce excess abdominal fat in HIV lipodystrophy). |
| How it works | Recombinant human growth hormone. Binds GH receptors to stimulate IGF-1 production, protein synthesis, and lipolysis. Promotes muscle growth, fat oxidation, and tissue repair. Structurally identical to pituitary GH, though injections don't reproduce its natural pulses. | Synthetic GHRH analogue FDA-approved for HIV-associated lipodystrophy. Stimulates GH secretion, reduces visceral adiposity, and improves body composition. Its half-life is short, close to sermorelin's (8–11 minutes on the current labels). |
| Commonly reported | Water retention, numb or tingling fingers, joint aches, and better sleep and skin. Requires careful dosing and IGF-1 monitoring — more is not always better. | Waist and belly shrinking while body weight barely moves, with injection-site redness and early joint aches. |
| Studied range | Research range: 1–4 IU. Studied in research — not a recommendation. | Research range: 1–2 mg. Studied in research — not a recommendation. FDA-approved as Egrifta WR (1.28 mg) and Egrifta SV (1.4 mg), SubQ once daily, to reduce excess abdominal fat in adults with HIV lipodystrophy. |
| How often | Daily SubQ injection. | Daily |
| Half-life | ~3-4 hours (SubQ) | ~8–11 min (current EGRIFTA SV/WR labels; the original label listed ~26 min) |
| Route | SubQ injection | SubQ injection |
| Typical run | Commonly reported starting dose 1-2 IU daily. Advanced users may run 3-4 IU split AM/PM. Cycles of 3-6+ months common. Monitor IGF-1 levels. Also run alongside peptide stacks; some advanced protocols add insulin, which isn't in this library. | FDA approval context: daily use. Community typically runs 12–24 weeks. Reassess at 3 months. |
| Evidence | Established: clinical trials or FDA-approved use exists | Established: clinical trials or FDA-approved use exists |
| Common side effects | Water retention, joint pain, carpal tunnel syndrome, morning fatigue, injection site reactions | Injection site reaction, fluid retention, joint pain, nausea, glucose dysregulation |
- Category
- HGHGrowth hormone
- TesamorelinGrowth hormone
- Also known as
- HGHGH, rHGH, Human Growth Hormone, Growth Hormone, Somatropin, hGH
- TesamorelinEgrifta
- What it is
- HGHRecombinant human growth hormone — an identical copy of the GH your pituitary makes.
- TesamorelinThe only GHRH analog currently FDA-approved (to reduce excess abdominal fat in HIV lipodystrophy).
- How it works
- HGHRecombinant human growth hormone. Binds GH receptors to stimulate IGF-1 production, protein synthesis, and lipolysis. Promotes muscle growth, fat oxidation, and tissue repair. Structurally identical to pituitary GH, though injections don't reproduce its natural pulses.
- TesamorelinSynthetic GHRH analogue FDA-approved for HIV-associated lipodystrophy. Stimulates GH secretion, reduces visceral adiposity, and improves body composition. Its half-life is short, close to sermorelin's (8–11 minutes on the current labels).
- Commonly reported
- HGHWater retention, numb or tingling fingers, joint aches, and better sleep and skin. Requires careful dosing and IGF-1 monitoring — more is not always better.
- TesamorelinWaist and belly shrinking while body weight barely moves, with injection-site redness and early joint aches.
- Studied range
- HGHResearch range: 1–4 IU. Studied in research — not a recommendation.
- TesamorelinResearch range: 1–2 mg. Studied in research — not a recommendation. FDA-approved as Egrifta WR (1.28 mg) and Egrifta SV (1.4 mg), SubQ once daily, to reduce excess abdominal fat in adults with HIV lipodystrophy.
- How often
- HGHDaily SubQ injection.
- TesamorelinDaily
- Half-life
- HGH~3-4 hours (SubQ)
- Tesamorelin~8–11 min (current EGRIFTA SV/WR labels; the original label listed ~26 min)
- Route
- HGHSubQ injection
- TesamorelinSubQ injection
- Typical run
- HGHCommonly reported starting dose 1-2 IU daily. Advanced users may run 3-4 IU split AM/PM. Cycles of 3-6+ months common. Monitor IGF-1 levels. Also run alongside peptide stacks; some advanced protocols add insulin, which isn't in this library.
- TesamorelinFDA approval context: daily use. Community typically runs 12–24 weeks. Reassess at 3 months.
- Evidence
- HGHEstablished: clinical trials or FDA-approved use exists
- TesamorelinEstablished: clinical trials or FDA-approved use exists
- Common side effects
- HGHWater retention, joint pain, carpal tunnel syndrome, morning fatigue, injection site reactions
- TesamorelinInjection site reaction, fluid retention, joint pain, nausea, glucose dysregulation
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
HGH
Week-by-week cards for HGH are not in our library.
Tesamorelin
- Day 1–14 Targeting the deep belly fat
- Day 14–56 Visceral fat is mobilizing
Questions people ask
How long do HGH and tesamorelin last?
The half-life of HGH is ~3-4 hours (SubQ). The half-life of tesamorelin is ~8–11 min (current EGRIFTA SV/WR labels; the original label listed ~26 min).
How often are HGH and tesamorelin taken?
HGH: daily SubQ injection. Route: SubQ injection. Tesamorelin: daily. Route: SubQ injection.
How are HGH and tesamorelin dosed in research?
The research range for HGH is 1–4 IU. Studied in research — not a recommendation. The research range for tesamorelin is 1–2 mg. Studied in research — not a recommendation. FDA-approved as Egrifta WR (1.28 mg) and Egrifta SV (1.4 mg), SubQ once daily, to reduce excess abdominal fat in adults with HIV lipodystrophy.
What are the common side effects of HGH and tesamorelin?
For HGH, the library lists: water retention, joint pain, carpal tunnel syndrome, morning fatigue, injection site reactions. For tesamorelin: injection site reaction, fluid retention, joint pain, nausea, glucose dysregulation.